Everything below concerns solid-phase synthesis. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-06-18. Numbers and descriptions here follow the published literature rather than marketing material.
Within the immune system, the peptide acts on several cell types rather than a single target. Reported activities include promotion of T-cell maturation, enhancement of natural killer cell activity, and modulation of cytokine production by dendritic cells and macrophages. Some of these effects appear to operate through toll-like receptor signaling, though the precise receptor-level mechanism remains debated. Whether the observed immune changes translate into clinical benefit is a separate question and depends on the indication studied.
The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids, corresponding to the N-terminal fragment of prothymosin alpha. Its sequence begins with acetylation at the N-terminus, a modification that affects stability and receptor interaction. The peptide is acidic, with a calculated isoelectric point near 4.2, and carries no disulfide bonds, so its secondary structure is largely flexible in solution. Molecular mass is approximately 3108 daltons. The native form was first isolated from bovine thymus tissue, while pharmaceutical material is produced by solid-phase peptide synthesis.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids whose sequence matches the amino-terminal region of prothymosin alpha. The chain is acetylated at its first residue and contains one disulfide bridge between two cysteine residues, which folds the molecule into a compact loop. Its molecular formula, C129H215N33O55, corresponds to a monoisotopic mass of roughly 3,106 daltons. Material used in laboratories is made by solid-phase synthesis rather than isolated from animal tissue.
Early work on thymic extracts in the 1960s described a heat-stable acidic fraction containing many polypeptides. Separation of that mixture yielded individual components, and thymosin alpha-1 was named as one of them on the basis of assays for T-cell activity. The first preparations came from calf thymus, while subsequent research and clinical material has been chemically synthesized. Nomenclature in older papers is inconsistent, and the same peptide sometimes appears under different designations, which complicates literature searches.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide, 28 residues | N-terminal fragment of prothymosin alpha |
| Molecular mass | About 3108 Da | Acetylated form |
| Isoelectric point | Near 4.2 | Acidic peptide |
| Appearance | White to off-white lyophilized powder | Common supplied form |
| Typical storage | -20 °C or below, dry | Solution stability is lower |
Thymosin alpha-1 is a synthetic peptide of 28 amino acid residues that corresponds to a naturally occurring fragment first isolated from thymus tissue. Its chain is acetylated at the amino terminus, a modification that shields the peptide from rapid cleavage by aminopeptidases. The molecule carries a net negative charge at physiological pH and dissolves freely in water. Researchers classify it as an immune-modulating agent rather than a classical hormone, because it acts on several cell types of both the innate and the adaptive immune system.
The peptide was identified during work in the 1970s on thymosin fraction 5, a partially purified extract of calf thymus. Investigators separated that mixture and characterized individual components, one of which they named thymosin alpha-1. The same compound later received the international nonproprietary name thymalfasin. Commercial material is produced by solid-phase peptide synthesis rather than by extraction, so synthetic and natural forms share an identical sequence. Naming conventions vary across the literature, and readers should distinguish the alpha-1 peptide from other thymosins that have unrelated sequences and functions.
Thymosin beta-4 is a separate 43-residue peptide that binds actin and participates in cell migration; it shares no sequence similarity with thymosin alpha-1 despite the common family name. Other preparative materials, such as thymosin fraction 5 and thymopoietin, contain distinct mixtures or peptides. The shared thymosin label reflects the tissue of origin used in early purification, not a common structural core. Treating these molecules as interchangeable is a frequent source of confusion in laboratory reports and in popular summaries alike.
Thymosin alpha 1 is a short peptide first isolated from bovine thymus tissue in the early 1970s during fractionation work aimed at identifying factors that influence T cell development. It belongs to a family of acidic thymic peptides, and the original preparations contained several components that were later separated by chromatography. The compound is now produced synthetically rather than extracted from tissue, which removes batch variability tied to animal sourcing. Researchers describe it as an immunomodulatory peptide because laboratory studies show effects on several cell types of the innate and adaptive immune systems.
The molecule consists of 28 amino acid residues with an acetyl group attached to the N-terminal serine. Its sequence is acidic overall, with several glutamic and aspartic acid residues distributed along the chain and no cysteine, so disulfide bridges do not form. The peptide carries a net negative charge at physiological pH. Because the N-terminus is blocked, the intact molecule resists degradation by many aminopeptidases, which contributes to its stability in biological fluids.
Lyophilized material is typically treated as a hygroscopic solid that should be brought to room temperature before the container is opened, which limits condensation on the powder. Reconstitution is commonly done with sterile water or a buffered diluent, and gentle mixing is preferred over vigorous agitation to reduce foaming and surface adsorption. Because peptides can bind to plastic and glass, diluents containing a small amount of carrier protein are sometimes used in laboratory work. Working solutions are generally aliquoted and prepared fresh rather than subjected to repeated freezing and thawing.
Stability depends on temperature, pH, and the number of freeze-thaw events the sample has experienced. Freeze-dried material is commonly held at -20 °C or colder, while reconstituted liquid is kept cold and used within a short window. Extreme pH and prolonged light exposure can promote deamidation, oxidation, or aggregation, particularly at asparagine and methionine positions. Adsorption to container walls can lower the measured concentration of a dilute solution even when the peptide molecules themselves remain intact.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
=== Mycotoxins and alimentary mycotoxicoses === The term alimentary mycotoxicosis refers to the effect of poisoning by mycotoxins through food consumption. The term mycotoxin is usually reserved for the toxic chemical compounds naturally produced by fungi that readily colonize crops under specific temperature and moisture conditions. Mycotoxins can have severe effects on human and animal health. For example, an outbreak which occurred in the UK during 1960 caused the death of 100,000 turkeys which had consumed aflatoxin-contaminated peanut meal. In the USSR in World War II, 5,000 people died due to alimentary toxic aleukia (ALA). In Kenya, mycotoxins led to the death of 125 people in 2004, after consumption of contaminated grain. In animals, mycotoxicosis targets organ systems such as the liver and digestive system. Other effects can include reduced productivity and suppression of the immune system, thus pre-disposing the animals to other secondary infections. Common foodborne mycotoxins include:
After a short career break, he returned to work in 1978, appearing in two stage productions: 1978's The Mighty Gents, winning a Drama Desk Award and a Clarence Derwent Award for his role as a wino, and White Pelicans. Freeman continued to work in theater and a year later, appeared in the Shakespearean tragedies Coriolanus, receiving the Obie Award in 1980 for the title role as well as Julius Caesar. In 1980, he had a small role as Walter in the drama Brubaker, which starred Robert Redford as a prison warden. Freeman next appeared in the television film, Attica (1980), which is about the 1971 Attica Prison riot and its aftermath. A year later he had a lead role in Peter Yates' Eyewitness with co-stars William Hurt and Sigourney Weaver. From 1982 to 1984, Freeman was a cast member of the soap opera Another World, playing architect Roy Bingham. After several small roles in dramas, he starred in Marie (1985), a film adaptation of Marie: A True Story by Peter Maas; he portrayed Charles Traughber. He also appeared in the miniseries The Atlanta Child Murders. Freeman also had a small role in the drama That Was Then... This Is Now, based on the novel of the same name by S. E. Hinton. In the mid-1980s, he began accepting prominent supporting roles in feature films, earning him a reputation for depicting wise, fatherly characters. In addition to television films, in 1987, Freeman played a violent street hustler, a role that diverged from his previous roles, in Street Smart co-starring Christopher Reeve and Kathy Baker.
== Rankings == The 2026 SCImago Institutions Rankings health-sector ranking for dentistry placed the West China Hospital of Stomatology first in China and third worldwide. In the 2025 ShanghaiRanking Global Ranking of Academic Subjects, Sichuan University was ranked fifth in the world in Dentistry & Oral Sciences. In the 2026 QS World University Rankings by Subject, Sichuan University was ranked 10th in the world for dentistry.
Sources: en.wikipedia.org
=== European Union === In 2006, the European Medicines Agency (EMA) issued a marketing authorization for the zoster vaccine to Sanofi Pasteur for routine vaccination in individuals aged 60 and over. In 2007, the EMA updated the marketing authorization for routine vaccination in individuals aged 50 and over. Shingrix was approved for medical use in the European Union in March 2018, with an indication for the prevention of herpes zoster (HZ) and post-herpetic neuralgia (PHN) in adults 50 years of age or older.
== One Health approach == Antimicrobial resistance (AMR) is commonly described within a One Health framework, which emphasizes the interconnected relationships between human health, animal health, and the environment. Antimicrobial use in clinical medicine, veterinary practice, and agriculture has been associated with the selection and spread of resistant microorganisms across these sectors. Research indicates that resistant bacteria and antimicrobial resistance genes can move between humans, animals, and environmental reservoirs through multiple pathways, including food production systems, direct contact, and exposure to contaminated water or soil. These pathways contribute to the persistence and wider dissemination of antimicrobial resistance beyond individual settings. Environmental sources have been increasingly examined in relation to AMR. Wastewater systems, agricultural runoff, and pharmaceutical residues have been identified as potential reservoirs where resistant microorganisms and resistance genes may persist. Such reservoirs may facilitate ongoing transmission between environmental, animal, and human populations. Efforts to address AMR within a One Health framework typically involve coordinated strategies across sectors, including antimicrobial stewardship, infection prevention and control, and improvements in sanitation and hygiene.
2021 – Myriad Morcells™ launched in USA for plastic and reconstructive surgery. 2022 – First scientific publication describing novel dead-space management negative pressure system. 2023 – Symphony™ launched in USA for advanced wound care.
Sources: en.wikipedia.org
== Subcellular distribution == The peptide recognition domain of epiplakin is able to bind to keratins in vitro; however, in cells the epiplakin associates with keratin intermediate filaments networks only under conditions in which cellular stress is absent. Otherwise, epiplakin remains universally cytoplasmic and not bound to the intermediate filaments.
He noted that shed scabs (which might be spread via bedsheets or other fomites) often contain “large quantities of virus”, but suggested that the “apparent lack of infectiousness of scab associated virus” might be due to “encapsulation with inspissated pus”. Contaminated needles are the most common fomite that transmits HIV. Fomites from dirty needles also easily spread Hepatitis B.
== Industrial uses == Micrococci, like many other representatives of the Actinobacteria, can be catabolically versatile, with the ability to utilize a wide range of unusual substrates, such as pyridine, herbicides, chlorinated biphenyls, and oil. They are likely involved in detoxification or biodegradation of many other environmental pollutants. Other Micrococcus isolates produce various useful products, such as long-chain (C21-C34) aliphatic hydrocarbons for lubricating oils.
Sources: en.wikipedia.org
It corresponds to a fragment of the larger protein prothymosin alpha, which is present in many tissues. The isolated 28-amino-acid peptide was originally obtained from thymus preparations, and the pharmaceutical product is synthesized rather than extracted. The term therefore describes both a natural fragment and a manufactured drug substance.
Thymosin alpha-1 is a single defined 28-residue peptide, while the broader family includes unrelated peptides such as thymosin beta-4. The shared name reflects historical isolation from thymus tissue rather than a common structure. Confusion between the two is common in older literature.
No single pathway fully accounts for its reported effects. Several studies describe interaction with innate immune receptors and downstream cytokine changes, but the complete picture is not settled. Open questions remain about which effects occur at physiological concentrations.
Its sequence corresponds to the amino-terminal portion of prothymosin alpha, a larger protein present in many cell types. The isolated 28-residue peptide is a fragment of that protein rather than a separately encoded molecule, and laboratory material is produced by synthesis.